These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9008464)

  • 1. Recombinant staphylokinase variants with altered immunoreactivity. III: Species variability of antibody binding patterns.
    Collen D; De Cock F; Demarsin E; Jenné S; Lasters I; Laroche Y; Warmerdam P; Jespers L
    Circulation; 1997 Jan; 95(2):455-62. PubMed ID: 9008464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant staphylokinase variants with altered immunoreactivity. IV: Identification of variants with reduced antibody induction but intact potency.
    Collen D; Stockx L; Lacroix H; Suy R; Vanderschueren S
    Circulation; 1997 Jan; 95(2):463-72. PubMed ID: 9008465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction.
    Collen D; Moreau H; Stockx L; Vanderschueren S
    Circulation; 1996 Jul; 94(2):207-16. PubMed ID: 8674180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization.
    Collen D; Bernaerts R; Declerck P; De Cock F; Demarsin E; Jenné S; Laroche Y; Lijnen HR; Silence K; Verstreken M
    Circulation; 1996 Jul; 94(2):197-206. PubMed ID: 8674179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative antigenicity of recombinant wild-type staphylokinase (SakSTAR) and a selected mutant (SakSTAR.M38) in a baboon thrombolysis model.
    Vanderschueren S; Stassen JM; Collen D
    J Cardiovasc Pharmacol; 1996 Jun; 27(6):809-15. PubMed ID: 8761847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes.
    Laroche Y; Heymans S; Capaert S; De Cock F; Demarsin E; Collen D
    Blood; 2000 Aug; 96(4):1425-32. PubMed ID: 10942387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single-bolus treatment of acute myocardial infarction.
    Collen D; Sinnaeve P; Demarsin E; Moreau H; De Maeyer M; Jespers L; Laroche Y; Van de Werf F
    Circulation; 2000 Oct; 102(15):1766-72. PubMed ID: 11023930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous removal of T and B cell epitope in recombinant staphylokinase by structure-based mutagenesis of immuno-dominant Arg77 and Glu80 residues.
    Xu R; He J; Jia K; Chen X; Liu J; Zhu K
    Wei Sheng Wu Xue Bao; 2011 May; 51(5):692-703. PubMed ID: 21800633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase.
    Vanwetswinkel S; Plaisance S; Zhi-Yong Z; Vanlinthout I; Brepoels K; Lasters I; Collen D; Jespers L
    Blood; 2000 Feb; 95(3):936-42. PubMed ID: 10648406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-function relationships in staphylokinase as revealed by "clustered charge to alanine" mutagenesis.
    Silence K; Hartmann M; Gührs KH; Gase A; Schlott B; Collen D; Lijnen HR
    J Biol Chem; 1995 Nov; 270(45):27192-8. PubMed ID: 7592976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential inhibition with antifibrinolytic agents of staphylokinase and streptokinase induced clot lysis.
    Lijnen HR; Stassen JM; Collen D
    Thromb Haemost; 1995 May; 73(5):845-9. PubMed ID: 7482414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous elimination of T- and B-cell epitope by structure-based mutagenesis of single Glu80 residue within recombinant staphylokinase.
    He J; Xu R; Chen X; Jia K; Zhou X; Zhu K
    Acta Biochim Biophys Sin (Shanghai); 2010 Mar; 42(3):209-15. PubMed ID: 20213046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons.
    Collen D; De Cock F; Stassen JM
    Circulation; 1993 Mar; 87(3):996-1006. PubMed ID: 8443918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of staphylokinase with human platelets.
    Lijnen HR; Van Hoef B; Collen D
    Thromb Haemost; 1995 Mar; 73(3):472-7. PubMed ID: 7667831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrin-selective thrombolytic therapy with recombinant staphylokinase.
    Collen D; Vanderschueren S; Van de Werf F
    Haemostasis; 1996 Oct; 26 Suppl 4():294-300. PubMed ID: 8979135
    [No Abstract]   [Full Text] [Related]  

  • 16. Construction of a novel Staphylokinase (SAK) mutant with low immunogenicity and its evaluation in rhesus monkey.
    Wang M; Chen Y; Fu W; Zou M; Wang Y; Xing W; Wang J; Xu D
    Int J Biol Macromol; 2020 Mar; 146():781-789. PubMed ID: 31730959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycosylation of asparagine-28 of recombinant staphylokinase with high-mannose-type oligosaccharides results in a protein with highly attenuated plasminogen activator activity.
    Miele RG; Prorok M; Costa VA; Castellino FJ
    J Biol Chem; 1999 Mar; 274(12):7769-76. PubMed ID: 10075668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicology studies with recombinant staphylokinase and with SY 161-P5, a polyethylene glycol-derivatized cysteine-substitution mutant.
    Moons L; Vanlinthout I; Roelants I; Moreadith R; Collen D; Rapold HJ
    Toxicol Pathol; 2001; 29(3):285-91. PubMed ID: 11442014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epitope mapping by negative selection of randomized antigen libraries displayed on filamentous phage.
    Jespers L; Jenné S; Lasters I; Collen D
    J Mol Biol; 1997 Jun; 269(5):704-18. PubMed ID: 9223635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and characterization of novel staphylokinase variants with antiplatelet aggregation activity and reduced immunogenecity.
    Su HB; Zhang YG; He JT; Mo W; Zhang YL; Tao XM; Song HY
    Acta Biochim Biophys Sin (Shanghai); 2004 May; 36(5):336-42. PubMed ID: 15156275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.